Zai Lab Limited American Depositary Shares (ZLAB) Stock
NASDAQ · ZLAB
25.89
Fundamentals
Market cap
$2.80B
Price / Earnings ratio
-15.1x
Price / Sales ratio
6.3x
Price / Book ratio
4.7x
Return on assets
-16.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Business Wire
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
NeutralZLABAugust 17, 2026
Business WireNeutral
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
ZLAB

MarketBeat
Zai Lab Q2 Earnings Call Highlights
NeutralZLABAugust 7, 2026
MarketBeatNeutral
Zai Lab Q2 Earnings Call Highlights
ZLAB

Zacks Investment Research
Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings
NeutralZLABAugust 6, 2026
Zacks Investment ResearchNeutral
Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings
ZLAB

Business Wire
Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates
NeutralZLABAugust 6, 2026
Business WireNeutral
Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates
ZLAB
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Buy12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy1
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
552M364M182M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
1B929M464M0
Revenue to Profit
2025$460.2M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-175.5M
Net incomeEarnings
EPS forecast
Actual EPS
$-0.14
Q1FY26
$0.20
Q2FY26
The market is expecting earnings per share of $0.20 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

Business Wire
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
NeutralZLABAugust 17, 2026
Business WireNeutral
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
ZLAB

MarketBeat
Zai Lab Q2 Earnings Call Highlights
NeutralZLABAugust 7, 2026
MarketBeatNeutral
Zai Lab Q2 Earnings Call Highlights
ZLAB

Zacks Investment Research
Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings
NeutralZLABAugust 6, 2026
Zacks Investment ResearchNeutral
Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings
ZLAB

Business Wire
Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates
NeutralZLABAugust 6, 2026
Business WireNeutral
Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates
ZLAB

Business Wire
U.S. FDA Grants Orphan Drug Designation to Zai Lab's DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)
NeutralZLABAugust 3, 2026
Business WireNeutral
U.S. FDA Grants Orphan Drug Designation to Zai Lab's DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)
ZLAB

Business Wire
Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026
NeutralZLABJuly 22, 2026
Business WireNeutral
Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026
ZLAB

Business Wire
Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas
NeutralZLABJune 16, 2026
Business WireNeutral
Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas
ZLAB

Business Wire
Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
NeutralZLABJune 9, 2026
Business WireNeutral
Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
ZLAB

Business Wire
Zai Lab Announces Changes to Senior Leadership Team
NeutralZLABMay 21, 2026
Business WireNeutral
Zai Lab Announces Changes to Senior Leadership Team
ZLAB

Business Wire
Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
NeutralZLABMay 11, 2026
Business WireNeutral
Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
ZLAB
About Zai Lab Limited American Depositary Shares
No description available.
SectorHealthcare
IndustryBiotechnology
Employees1,784
CEODr. Ying Du Ph.D.
IPO DateSep 20, 2017
HeadquartersPudong, China
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Ying Du Ph.D. | Founder, Chairperson & CEO | 1966 |
| Dr. Rafael G. Amado M.D. | President and Head of Global Research & Development | 1964 |
| Dr. Yajing Chen Ph.D. | Chief Financial Officer | 1968 |
| Mr. Frazor Titus Edmondson III, J.D. | Chief Legal Officer & Corporate Secretary | 1966 |
| Ms. Christine Chiou | Senior VP & Head of Investor Relations | — |
| Dr. James Yan DABT, M.D., Ph.D. | Chief Operating Officer of Global R&D | 1964 |
| Dr. Shan He Ph.D. | Senior VP & Chief Business Officer | — |
Fundamentals
Valuation
Market cap$2.80B
Price-to-sales ratio6.31
Price-to-book value4.68
Price-earnings ratio-15.10
Return on Equity-24.00%
Return on Sales-38.00%
Return on Assets-16.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-1.80
Income Statement
Average volume877,171
EBITDA$-150.27M
1 year high (52w)$34.72
1 year low (52w)$15.96
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Buy12 Indicators
What the experts say
1 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$45.00
Est return
73.75%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -1.5 | +1.6 | -33.7 | -11.8 | ||||||||
| 2022 | -22.9 | +2.1 | -16.3 | -12.1 | -26.4 | +17.6 | +5.2 | +18.9 | -26.1 | -35.0 | +54.1 | -15.1 |
| 2023 | +36.6 | -12.6 | -17.6 | +3.0 | -6.6 | -16.0 | +4.5 | -13.2 | -6.9 | +5.7 | +10.3 | -0.6 |
| 2024 | -17.2 | -6.8 | -24.1 | -5.5 | +11.8 | -3.7 | +10.1 | +8.1 | +24.8 | +21.6 | -5.3 | -10.3 |
| 2025 | +9.6 | +26.5 | +13.9 | -15.0 | -3.2 | +12.1 | +7.5 | -10.1 | +1.6 | -24.1 | -23.7 | -11.3 |
| 2026 | -4.2 | +17.9 | +2.1 | +6.4 | -17.9 | +11.2 | -4.6 | +40.0 | -1.3 |



